Abstract | Over the past two decades, most guidelines have advocated early initiation of dialysis on the basis of studies showing improved survival in patients starting dialysis early. These recommendations led to an increase in the proportion of patients initiating dialysis with an estimated glomerular filtration rate (eGFR) >10 ml/min/1.73 m 2 , from 20% in 1996 to 52% in 2008. During this period, the percentage of patients starting dialysis with an eGFR ≥15 ml/min/1.73 m 2 increased from 4% to 17%. However, recent studies have failed to substantiate a benefit of early dialysis initiation and some data have suggested worse outcomes for patients starting dialysis with a higher eGFR. Several reasons for this seemingly paradoxical observation have been suggested, including the fact that patients requiring early dialysis are likely to have more severe symptoms and comorbidities, leading to confounding by indication, as well as biological mechanisms that causally relate early dialysis therapy to adverse outcomes. Patients with a failing renal allograft who reinitiate dialysis encounter similar problems. However, unique factors associated with a failed allograft means that the optimal timing of dialysis initiation in failed transplant patients might differ from that in transplant-naive patients with chronic kidney disease. In this Review, we discuss studies of dialysis initiation and compare risks and benefits of early versus late initiation and reinitiation of dialysis therapy.
Introduction
In 1997, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative recommended that dialysis should start at a urea clearance (Kt/V urea ) of <2.0 per week. ) is reached for patients with symptoms associated with existing comorbidities and insufficient renal function. 2 A European Best Practice guideline published in 2002 recommended that dialysis be started when GFR is between 8 ml/min/1.73 m 2 and 10 ml/min/1.73 m 2 if the patient has symptoms such as signs of uremia and uncontrolled blood pressure. 3 This guideline was revised in 2011, however, and now states "it should be taken into account that the majority of patients will be symptomatic and need to start dialysis with GFR in the range 6-9 ml/min/1.73 m 2 ". 4 Based on these guidelines, dialysis therapy is initiated between 10 ml/min/1.73 m 2 and 15 ml/ min/1.73 m 2 in most patients with CKD in the USA. 5 Data from the US Renal Data System (USRDS) show that between 1996 and 2008, the proportion of patients initiating hemodialysis with an estimated GFR (eGFR) of >10 ml/min/1.73 m 2 increased from 20% to 52%, and those starting with an eGFR of ≥15 ml/min/1.73 m 2 increased from 4% to 17%. 6, 7 Interestingly, observational studies from the past decade and a randomized, controlled trial published in 2010 failed to support the benefit of early dialysis initiation in patients with CKD. 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In contrast to transplant-naive patients with CKD, only limited data are available on failed kidney transplant patients who need dialysis reinitiation. Failed kidney transplant recipients seem to have worse clinical outcomes than their transplant-naive counterparts, 19, 20 including worse survival on hemodialysis 19 or peritoneal dialysis therapy. [21] [22] [23] [24] [25] [26] Indeed, the incidence and prevalence of dialysis-dependent end-stage renal disease (ESRD) as a result of complications after transplantation have increased dramatically, from 0.3 per million and 3.3 per million in 1996-1998 to 1.4 per million and 4.8 per million in 2006-2008, respectively. 5 During 2006-2008, the annual cost of hemodialysis and transplantation per patient was US$77,506 and $26,668, respectively, suggesting that each extra year with a functioning transplant instead of on dialysis would save $50,838. 5 Theoretically, over $500 million could have been saved if each year 10,000 transplanted patients had an extra year with a functioning allograft before initiating dialysis. Similar findings are seen in transplant-naive patients. During 2006-2008, the annual cost per patient on hemodialysis and per highrisk patient with CKD (patients with CKD and heart failure) was $77,506 and $35,000, respectively, which suggests that each extra year that dialysis is delayed would save approximately $40,000. 5 Therefore, although there are important clinical and economic implications from the findings of dialysis initiation studies in transplant-naive patients with CKD, revisiting this issue in failed kidney transplant patients could have even greater overarching consequences, especially as the ideal timing of dialysis initiation in failed kidney transplant patients and the financial implications are unknown. Given the exposure to immunosuppressive drugs and other unique factors associated with a failing allograft, the timing of dialysis initiation and its consequences could differ in failed transplant patients and in their transplant-naive counterparts. In this Review, we examine data pertaining to the association between the eGFR at initiation of dialysis and outcomes in both transplant-naive patients with CKD and in failed kidney transplant recipients.
Early versus late dialysis initiation
Since the mid-1970s, several observational studies have supported the early initiation of dialysis in patients with CKD. These studies were small and some did not adjust for age or comorbidities, which differed significantly between the early and late dialysis initiation groups. [27] [28] [29] [30] [31] [32] [33] Despite the rather weak evidence, early initiation was almost universally recommended as the better choice. A number of studies published in the past decade, however, including a randomized controlled trial, have cast doubt on the benefits of early initiation of dialysis in patients with CKD. 6, 9, 10, 13, [16] [17] [18] 34 Figure 1 summarizes studies that have compared early versus late dialysis initiation in transplant-naive patients with CKD and in failed kidney transplant patients.
Data in support of early dialysis initiation
Several factors are associated with the early initiation of dialysis ( Figure 2 ). Practice guidelines outlined Key points ■ Late initiation of dialysis is not associated with worse mortality in transplantnaive patients with chronic kidney disease compared with mortality in patients who start dialysis early ■ Current guidelines suggest that the majority of transplant-naive patients will be symptomatic and need to start dialysis with an estimated glomerular filtration rate (eGFR) in the 6-9 ml/min/1.73 m 2 range ■ In patients with a failing kidney transplant, there is a paucity of evidence for or against early reinitiation of dialysis treatment ■ Factors such as predialysis care, late referral, dialysis dose, timing of immunosuppression reduction and residual function of the renal allograft might modify the association between dialysis reinitiation and outcomes in failed transplant recipients ■ Several biological factors, including hemodynamic instability, loss of residual renal function and a high infection rate, might contribute to the increased mortality risk associated with dialysis initiation ■ Starting dialysis early solely based on eGFR is not justified and could in fact be harmful in some cases; therefore, alternative and more reliable measures of a patient's clinical condition are required by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative in 1997 recommended that renal replacement therapy should be considered when GFR declines below 10.5 ml/min/1.73 m 2 , and should be implemented in the event of unintentional weight loss, a decrease in weight-normalized protein intake of <0.8 g/kg per day, or clinical signs or symptoms of uremia. 1 These recommendations were based on the assumption that the early initiation of dialysis might improve the nutritional status of patients on dialysis, thus leading to improved survival. [27] [28] [29] 32 These guidelines led to a notable trend towards earlier initiation of 35 To the best of our knowledge, the few studies that support early dialysis initiation are mostly from 15-20 years ago. [27] [28] [29] [30] [31] [32] [33] A study from 1976 found that earlier dialysis initiation had superior results, 27 with supporting follow-up studies performed in 1978 and 1985. 28, 29 These studies, [27] [28] [29] however, had no data on age, comorbidity, quality of life, or censored survival. Ratcliffe et al. compared the survival of patients in early versus late referral groups in the UK. 30 Patients in the early referral group were in the care of a nephrologist for a mean of 4 years before dialysis initiation. Of the patients referred late and starting dialysis with residual renal function (RRF) <6 ml/ min/1.73 m 2 , 70% of patients required prolonged hospitalization, during which mortality was 13%. By contrast, in the early referral group who had RRF ≥6 ml/min/1.73 m 2 at dialysis start, only 9% of patients required prolonged hospitalization and mortality was 4%. 30 Similar results were found in other studies. 31, 32 Perhaps the most convincing data in support of early dialysis initiation came from the Canada-USA (CANUSA) study of patients on peritoneal dialysis. 33, 36 For patients with an initial GFR >3.8 ml/ min, the 12-month and 24-month survival was 94.7% and 82.1%, respectively, compared with 90.8% and 73.6% for those with a GFR <3.8 ml/min (P = 0.015) at dialysis initiation. 33, 37 Although patients with an initial renal Kt/ V urea >0.71 had better survival than those with an initial Kt/V urea <0.71, the difference was not statistically significant (P = 0.10). 33, 37 Controlling for age, diabetes mellitus, cardio vascular disease, country, and serum albumin concentration, the death risk of 0.95 for a 0.5 ml/min increase in GFR at initiation of dialysis was notable. 33, 37 Mortality can also be high in patients with a low eGFR who are not on dialysis. A study from 2011 showed that mortality among nondialyzed patients increased significantly at an eGFR <7.5 ml/min (hazard ratio [HR] 4.65, 95% CI 2.28-9.49) compared with an eGFR 7.5-10 ml/min. 18 The studies discussed above were all observational and therefore have important limitations. The apparent survival gain of early dialysis initiation in these studies is likely owing to lead-time bias (rather than an actual improvement in the course of the disease). 8 Another major source of bias in these studies is confounding by indication, whereby the severity of a patient's symptoms might determine the timing of dialysis initiation. Although a randomized controlled trial would avoid this issue, the magnitude of confounding by indication could be somewhat mitigated by using novel statistical techniques such as the propensity score 10 or instrumental variables in observational studies. To our knowledge, only one study used these methods; the results did not support the early initiation of dialysis but identified several predictors of early initiation, such as sex, race, presence of comorbidities, BMI and serum albumin level. 10 Another important source of bias and error in these studies is the use of eGFR instead of true creatinine clearance. An early study showed that patients with low creatinine levels were malnourished and that predialysis patients with CKD and protein-energy wasting, including sarcopenia or low meat intake (as a result of a diminished appetite or recommended low-protein diet), had lower serum creati nine levels and perhaps lower creatinine clearance rates but paradoxically higher eGFR calculated using the Modification of Diet in Renal Disease (MDRD) formula at initiation of dialysis. 38 Serum creati nine level has been suggested to be a good indicator of muscle mass under steady-state conditions in patients on maintenance hemodialysis. [39] [40] [41] Indeed, Beddhu et al. reported that higher eGFR (as assessed using the MDRD formula) at dialysis initiation, but not higher creatinine clearance, was associated with an increased risk of death. 10 Whether the observed associations are due to confounding by indication and/or other sources of bias, or whether they are true and causal associations with biological plausibility is therefore not clear (Figure 3 ).
Data against early dialysis initiation
Several studies have questioned the beneficial effects of early dialysis initiation. 42 In one observational study, a small beneficial effect of early dialysis initiation of 2.5 months in the first 3 years was found after the start of dialysis, but this gain was apparently an overestimation caused by the lead time. 8 In another study, higher eGFR at dialysis initiation was associated with an increased risk of death, although in a subgroup of patients with measured creatinine clearance this calculation of renal function was not significantly associated with decreased or increased mortality. 10 Traynor et al. found that higher creatinine clearance (≥8.3 ml/min) at initiation of dialysis was associated with elevated mortality risk. 9 Similarly, a large observational study from the USA found a dosedependent increase in mortality with earlier dialysis initiation. 16 After correcting for other factors, patients who initiated dialysis with a higher eGFR experienced a 44% increased mortality risk compared with patients who started dialysis with an eGFR of 5-10 ml/min/1.73 m 2 , whereas those who initiated dialysis at the lowest eGFR (<5 ml/min/1.73 m 2 ) had a 12% lower death risk. 16 Similar results were reported in a large observational study from Europe. An important limitation of the studies mentioned above is that the early and late initiation groups of patients had significantly different case-mix and risk-factor profiles ( Figure 3) . Patients who start dialysis early are more likely to be men, have diabetes mellitus, more severe heart failure or coronary heart disease, lower serum albumin levels and more comorbidities, and are less likely to have glomerulonephritis or polycystic kidney disease; thus, these patients are 'sicker' . 6, 10, 15, 18 Although comorbidity is an important confounder, the increased risk of death associated with early dialysis initiation is not fully explained by comorbidities. 11, 12, 15 Wilson et al. reported that preexisting morbid conditions are more important determinants of 2-year dialysis survival than the timing of dialysis initiation. 12 This finding was confirmed in a study that included more than 10,000 patients, in which higher eGFR was associated with an increased mortality risk. 15 This association was weakened but remained statistically significant after adjusting for age and comorbidity. 15 Hence, the above-mentioned observational studies are prone to biases related to lead time, patient selection, referral time and the confounding by indication (Figure 3) .
Data from randomized, controlled trials that examined the optimal timing for the initiation of dialysis were lacking until 2010, when the results of the Initiating Dialysis Early and Late (IDEAL) study were published. 17, 34 Patients were eligible for the IDEAL study if they had progressive CKD (including a failing kidney transplant) and an eGFR between 10 ml/min/1.73 m 2 and 15 ml/min/1.73 m 2 . The eGFR was estimated using the Cockcroft-Gault equation and corrected for body-surface area. 43 Patients were randomly assigned to either commence dialysis with an eGFR of 10-14 ml/min/1.73 m 2 (early-start group) or to continue to receive routine medical care and commence dialysis with an eGFR of 5-7 ml/min/1.73 m 2 (late-start group). 34 During a median follow-up of 3.6 years, 37.6% (152 of 404 patients) of early starters and 36.6% (155 of 424 patients) of late starters died (HR for early initiation 1.04, 95% CI 0.83-1.30; P = 0.75). 17 The authors concluded that, with careful clinical management, dialysis can be safely delayed for some patients until eGFR falls below 7 ml/min/1.73 m 2 or until traditional clinical indicators are present. 17 Although randomized, controlled trials provide the best type of evidence, questions always remain about the generalizability of their results. 44 In the IDEAL study, the mean pre dialysis eGFR differed only slightly between the two groups (2.2 ml/min by the Cockcroft-Gault equation and 1.8 ml/min by the MDRD equation). 45 This difference is smaller than what was prespecified by the study protocol (5-7 ml/min/1.73 m 2 ). Moreover, there was a striking between-group difference in the rate of uremia, which developed in only 7% of patients in the earlystart group compared with 73% in the late-start group. Worsening uremia might affect health-related quality of life. Indeed, quality of life was significantly better in the first year of dialysis in patients with early compared with late start of dialysis in one study. 46 Additionally, the IDEAL study is not representative of incident dialysis patients in the USA and Europe. 4, 7 Data from the USRDS suggest that approximately 50% of incident dialysis patients are aged >65 years, 5,7 whereas the mean age of patients in the IDEAL study was 60 years. In addition, approximately 40% of patients in the IDEAL study had cardiovascular disease, whereas USRDS data suggest that this complication occurs in approximately 60% of patients with stage 4 or 5 CKD. 7 The results of the IDEAL study should therefore be interpreted with caution. 47 
Dialysis in failed transplant patients
In the USA, kidney allograft loss is an important cause of dialysis initiation. The incidence of ESRD owing to complications after transplantation was twofold higher in 2006-2008 than 10 years earlier (Figure 4) . 5 A similar trend in Europe and Australia might exist, but neither the ERA-EDTA registry nor ANZDATA collect data relating to the number of patients who return to dialysis therapy following a failed kidney transplant. An analysis of the USRDS database found that 1-year, 2-year and 3-year all-cause mortality was 16%, 25% and 33%, respectively, in failed kidney transplant patients on dialysis. 48 Cardiac and infectious diseases were the main causes of death. 48 The use of peritoneal dialysis compared with hemo dialysis was associated with similar early and overall mortality among patients returning to dialysis after a failed transplant. 49 Interestingly, these patients had worse survival than renal allograft recipients whose dialysis therapy was delayed after a failed transplant. 50 Indeed, current evidence indicates that, despite similar comorbidity profiles, the survival of patients on dialysis after a failed transplant is worse than incident waitlisted transplant-naive patients on dialysis. 19 Some potential explanations for this survival difference exist (Table 1) . First, failed transplant patients on dialysis have an increased risk of infection caused by the effects of exposure to chronic immuno suppression. Septicemia rates in these patients are particularly high during the first few months after starting dialysis, which might be related in part to the use of temporary hemo dialysis catheters during which time residual immuno suppression might continue for months to years following dialysis reinitiation. 51 Second, compared with incident transplant-naive patients on dialysis, failed transplant patients might receive sub optimal predialysis care as many physicians focus on immunosuppression rather than on predialysis care, which could contribute to morbidity after dialysis reinitiation. 48, 52, 53 Failed transplant patients usually have increased exposure to uremia owing to longer dialysis vintage and therefore are more predisposed to the effects of anemia, erythropoietin resistance, hypoalbuminemia, mineral and bone disorders, and other conditions associated with reduced survival. 20, [53] [54] [55] Third, the presence of a failed allograft remnant might be an ongoing source of chronic inflammation, which is a known risk factor for mortality both in patients on dialysis and in kidney transplant recipients. 56, 57 Early initiation of dialysis with an allograft that is still viable is likely to be associated with such adverse immunological and inflammatory reactions, although this hypothesis remains to be proven. Finally, preserved urine output is a strong predictor of patient survival in incident patients on dialysis. 58 However, little is known about the impact of RRF on survival in failed transplant patients on dialysis. A decline in RRF is known to occur faster in failed transplant patients than in transplantnaive patients. 26 Based on striking differences between transplant-naive and failed kidney transplant patients, including exposure to immunosuppressive medications, studies in transplant-naive patients with CKD might not be generalizable to patients with a failed renal allograft.
Dialysis reinitiation in transplant patients
To the best of our knowledge, only two studies have assessed the association between eGFR at reinitiation of dialysis and mortality in failed kidney transplant patients. 48, 59 Gill et al. examined 4,741 failed kidney transplant patients for more than 1 year after reinitiation of dialysis in the USA. 48 During the follow-up period, 1,016 patients (21%) died, mostly owing to cardiac (36%) and infectious (17%) causes. The eGFR was significantly higher at dialysis reinitiation in patients who died than in survivors (9.7 ± 4.8 ml/min/1.73 m 2 versus 8.0 ± 3.7 ml/ min/1.73 m 2 ). Each ml/min/1.73 m 2 increase in eGFR at dialysis reinitiation was associated with a 4% increased risk of death during dialysis (HR 1.04, 95% CI 1.02-1.06). 48 Although this study is pioneering, it has several limitations that are similar to those seen in studies of transplant-naive patients, including confounding by indication, that is, the sickest patients tend to require dialysis initiation at higher RRF levels. 48 This confounding by indication could have been addressed at least partially with the use of propensity scores as was done in one study of transplant-naive patients with CKD 10 and a recent study in failed transplant recipients, 59 or by using an instrumental variable. In a cohort study of 747 failed kidney transplant patients who had returned to dialysis therapy, a propensity score for the likelihood of early (eGFR between ≥10.5 ml/min/1.73 m 2 and <15 ml/min/1.73 m 2 ) versus late (eGFR <10.5 ml/ min/1.73 m 2 ) dialysis therapy reinitiation was fitted by logistic regression. Although patients with early initiation of dialysis appeared sicker (more patients in this group had diabetes mellitus and heart disease and lower BMI), there was no survival advantage of earlier dialysis therapy in any group. Patients with a higher eGFR upon reinitiation of dialysis exhibited a trend towards an increased risk of mortality; this trend was most prominent among the healthiest subgroups of patients identified by the propensity score, including women and younger individuals. 59 To date, neither additional observational studies nor any randomized, controlled trials have answered the important question as to whether early or late reinitiation of dialysis is better in failed kidney transplant patients.
Factors that modify dialysis outcomes Some potential factors might modify the association between dialysis reinitiation and outcomes in failed kidney transplant recipients. First, the cause and time course of first transplant failure might modify this association. Patients with a primary nonfunctioning graft or hyperacute rejection may require immediate allograft nephrectomy, have no renal function and belong to a late reinitiation group. Second, differences found in observational studies among patients who start early versus late dialysis might relate to predialysis care by a renal care professional, as well as other markers of optimal dialysis initiation such as vascular access type and location of dialysis initiation (for example, in centers with more specialized care). 60 Third, late referral to a nephrologist also has an impact on survival. In a meta-analysis from 2007, late referral was associated with a significantly increased risk of all-cause mortality (risk ratio 1.99, 95% CI 1.66-2.39) and 1-year mortality (risk ratio 2.08, 95% CI 1.31-3.31) compared with early referral. 61 Fourth, the dialysis dose at initiation of dialysis might have an impact on the association between dialysis reinitiation and outcomes. Fifth, the type of dialysis modality at initiation also has an effect on mortality although it is not yet known whether starting hemodialysis early would have a different effect from starting peritoneal dialysis early. Finally, the timing of reduction of immuno suppression and graft removal might have an effect on this association. In patients with late graft failure (graft survival >1 year), removal of the graft may improve survival and enable the physician to stop immunosuppression shortly after the reinitiation of dialysis. 62 
Biological contributors to outcomes
A number of biological factors might causally contribute to the increased risk of mortality upon early initiation of dialysis (Table 2 ). In patients who start dialysis relatively late, the harmful aspects of some of these factors might be mitigated or perceived to be less when compared with patients with a shorter dialysis-free period. Thrice-weekly hemodialysis treatment could lead to subtle but cumulative mechanical and oxidative stress on the cardio vascular system and could give rise to hemo dynamic instability. Although biocompatible membranes seem to be associated with better survival than cellulose membranes, bioincompatibility still remains a problem that might contribute to elevated inflammation or infection and oxidative stress. 63 Moreover, the infection rate is extremely high after initiation of dialysis. In a US Medicare cohort of patients who had newly started on dialysis between 1996 and 2001, the 1-year incidence of infection-related hospitalizations was 32% for those who received hemodialysis and 24% for those who received peritoneal dialysis; the 3-year incidence of infection-related hospitalizations exceeded 50% in both groups. 64 In the HEMO study, however, most infection-related hospitalizations were not attributed to vascular access. 65 Additionally, the frequency of infection-related hospitalizations relating to access was disproportionately higher among patients with catheters than among those with grafts or fistulas. 65 Repeated bouts of acute tubular necrosis as a result of low blood pressure during each hemodialysis session 66 could lead to a faster loss of residual kidney function and frequent ischemic events with hypotensive episodes. Exposure to toxic medications might also have a role. Patient anxiety that accompanies each hemodialysis treatment, along with fatigue and lightheadedness following sessions, might aggravate harm. 
REVIEWS
Another factor that could explain the association between high eGFR and mortality is sarcopenia. eGFR is an inaccurate measure of true GFR in patients with stage 5 CKD as calculations to estimate GFR are often based on serum creatinine levels, which reflects muscle mass. 68 Therefore, a high eGFR in patients with stage 5 CKD may reflect sarcopenia (which leads to low creati nine levels), not better renal function. [69] [70] [71] Sarcopenia is in turn a predictor of poor outcomes in hemodialysis. 72 Earlystart dialysis based on creatinine clearance as a measure of kidney function (a better measure in stage 5 CKD) might or might not have an adverse effect on mortality risk. 10 Moreover, most equations used to estimate GFR tend to overestimate GFR in kidney transplant recipients. A study examining 12 different methods found that the Walser and MDRD equations gave the best performance to estimate GFR in kidney transplant recipients. 73 Prolonging the predialysis period For decades, there have been minority camps within the nephrology community advocating late-start dialysis initiation. A nonrandomized study suggested increased survival in the early dialysis period if patients received a low-protein diet. 74 The strategy of maintaining a lowprotein diet (0.6-0.7 g/kg per day) while providing amino acids and proteins of high biological value is one approach to protect kidney function. In many countries outside the USA, ketoanalogues are used routinely, as are indoxyl sulfate modulators and adsorbents. Increased circulating indoxyl sulfate levels are associated with inflammation, oxidative stress, endothelial dysfunction, vascular calcification and mortality in patients with CKD. 75 Thus, the removal of indoxyl sulfate by AST-120 (an oral indoxyl sulfate adsorbent) could ameliorate the progression of not only CKD, but also of cardiovascular disease and osteodystrophy related to CKD. 76, 77 More recently, bardoxolone methyl, an oral antioxidant inflammation modulator, was associated with improvement in the eGFR at 24 weeks in patients with advanced CKD and type 2 diabetes mellitus. 78 This improvement persisted at 52 weeks, indicating that bardoxolone methyl could have promise for the treatment of patients with CKD. 78 Even though the results of this study are promising, it is important to note that only eGFR (using the MDRD equation) was measured, which is based on serum creatinine level and hence muscle mass. 41 The most common adverse event noted in this study was muscle spasm, which was 2-3-fold higher in the bardoxolone methyl group. Moreover, in the treatment group, patients reported 3-4-times higher rates of appetite loss and weight loss of several kilograms compared with the placebo group. 78 In addition to the aforementioned interventions, salt and fluid restriction with or without diuretics might contribute to prolongation of the dialysis-independent period and late initiation of dialysis. Finally, alkali therapy such as bicarbonate slows the rate of progression of renal failure to ESRD and improves nutritional status among patients with CKD.
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Conclusions
Since the emergence of recent observational studies and the IDEAL trial, the European Best Practice Guidelines have changed their recommendations of dialysis initiation. The presence of symptoms, diabetes mellitus and rapid deterioration of RRF has now become more important than eGFR in deciding when to initiate dialysis. These guidelines suggest that the majority of patients will be symptomatic and need to start dialysis with an eGFR in the 6-9 ml/min/1.73 m 2 range. 4, 68 Similar recommendations for late dialysis initiation have been suggested in an increasing number of publications. 42, 44 We feel that starting dialysis early solely based on an eGFR is not justified and could in fact be harmful in some cases of transplant-naive and failed transplant patients. Although other studies indicate that starting dialysis with an eGFR >7 ml/min/1.73 m 2 is not necessarily associated with an increased mortality risk, these results may reflect survivor bias. The concept of depending on this single metric for such a crucial decision is likely to be flawed, and alternative and reliable measures are required. In failed kidney transplant patients there is an even larger paucity of evidence for or against early reinitiation of dialysis. The available limited data suggest, however, that failed kidney transplant patients differ considerably from transplant-naive patients with CKD, and hence the association between initiation of dialysis and outcomes may also differ substantially. Observational and controlled studies are needed to examine this important area of daily clinical practice in the nephrology and transplantation arenas.
Review criteria
Material for this Review was obtained by searching the PubMed database using the following terms (alone and in various combinations): "dialysis", "peritoneal dialysis", "hemodialysis", "initiation", "start", "transplantation", "kidney transplantation", "graft loss", "graft failure", "glomerular filtration rate", "creatinine clearance", "outcome" and "mortality". Data for this Review were obtained by searching the USRDS, ERA-EDTA and ANZDATA databases. Selected articles were full-length, English-language papers, with a focus on studies of dialysis initiation and on papers published since 1980. The reference lists of identified papers were searched for further relevant material.
